Anavex Life Sciences Corp (AVXL)

[Gator328]

Adding to your point, I believe we haven’t reached the part where Dr. Missling’s talent will shine. A lot of these science-minded biotech CEOs struggle when it comes to running a profitable business. The fact that Dr. Missling is running several concurrent trials for multiple diseases, with $100 million in the back, no debt, fewer than 100 million shares issued and a poison pill to thwart a takeover is all I need to see to know he’s going to be a good post-revenue CEO.

As for the missed deadlines, I’m sure that Dr. Missling would love for everything to be complete. Is it possible he’s trying to bleed the coffers? Sure. But it’s more likely there are delays because…delays happen. I am patient.

And I just don’t see Dr. Missling using smoke and mirror tactics to claim statistical significance. Too much risk to walk the fine line with the SEC, when he could easily just announce that another trial is needed or he’s pivoting to A371 and Rett.

Speaking of Rett, even if that’s all Anavex had in its pipeline it would still be undervalued at $9/share. Blarcamesine has very good odds of approval for Rett because there are no approved alternatives, the Rett community supports Anavex and there’s anecdotal evidence that it works.

If Blarcamesine works for anything else, I’ll consider it a wonderful bonus.